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Background: Women who develop secondary arm lymphoedema subsequent to treatment associated with breast
cancer require life-long management for a range of symptoms including arm swelling, heaviness, tightness in the
arm and sometimes the chest, upper body impairment and changes to a range of parameters relating to quality of
life. While exercise under controlled conditions has had positive outcomes, the impact of yoga has not been
investigated. The aim of this study is to determine the effectiveness of yoga in the physical and psycho-social
domains, in the hope that women can be offered another safe, holistic modality to help control many, if not all, of
the effects of secondary arm lymphoedema.
Methods and design: A randomised controlled pilot trial will be conducted in Hobart and Launceston with a total
of 40 women receiving either yoga intervention or current best practice care. Intervention will consist of eight
weeks of a weekly teacher-led yoga class with a home-based daily yoga practice delivered by DVD. Primary
outcome measures will be the effects of yoga on lymphoedema and its associated symptoms and quality of life.
Secondary outcome measures will be range of motion of the arm and thoracic spine, shoulder strength, and
weekly and daily physical activity. Primary and secondary outcomes will be measured at baseline, weeks four, eight
and a four week follow up at week twelve. Range of motion of the spine, in a self-nominated group, will be
measured at baseline, weeks eight and twelve. A further outcome will be the women’s perceptions of the yoga
collected by interview at week eight.
Discussion: The results of this trial will provide information on the safety and effectiveness of yoga for women with
secondary arm lymphoedema from breast cancer treatment. It will also inform methodology for future, larger trials.
Trial registration: ACTRN12611000202965
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Breast cancer- related lymphoedema (BCRL) is a result
of disruption to the lymphatic transport system as a re-
sult of a number of procedures associated with the treat-
ment of breast cancer [1]. BCRL is associated with
chronic or recurring swelling of the affected area and
underlain by cellular and tissue changes, making the
area more prone to infections. High risk indicators for
lymphoedema onset are mastectomy, radiation to the ax-
illa, axillary dissection and removal of a high number of
lymph nodes [2]. In spite of recent changes to surgical* Correspondence: AndrewWilliams@utas.edu.au
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reproduction in any medium, provided the orand radiological procedures for breast cancer, at least
20% of women are still affected [3]. As breast cancer in-
cidence continues to rise [4], a significant number of
women will continue to get secondary lymphoedema.
While the arm is the most common site, the chest,
upper back or breast are also often involved. As these
areas are difficult to measure, current incidence rates are
likely to be significantly underestimated.
The loss of upper body function can be higher for
women with BCRL than for those treated for breast can-
cer without lymphoedema [5]. Physical activity can be
reduced not only due to the swelling, but also as a con-
sequence of the changed sensations [6], pain [7] and fa-
tigue [8], as well as women’s fear of exacerbating the
symptoms of lymphoedema [9]. Women commonlyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of their affected shoulder and limitations in various daily
activities that depend on carrying, repetitive actions or
having their arm in the same position for a prolonged
period [10]. Biomechanics of the thoracic-shoulder area
can be compromised [11,12], which can create further
upper body impairment. Additionally, women experience
feelings of abandonment and isolation, compounded by
uncertainty and poor body image [13,14], which can lead
to a lowered quality of life in physical, social, personal
and emotional domains [15].
BCRL requires early recognition, targeted treatment
and self-management for life to reduce the risk of infec-
tion and prevent the condition worsening. Treatment
may include complex lymphoedema therapy involving
manual lymphatic drainage (MLD) with compression
bandaging as required, and daily self-management,
which focuses on skin care, self-massage, specific exer-
cises with deep breathing and wearing a compression
sleeve [16,17]. Motivation and compliance with self-care
are difficult to maintain [18] due to treatment fatigue
and a feeling of frustration that the limb is not getting
significantly better.
Participation in exercise is increasingly recommended
as another option for women with BCRL to improve
their physical and mental health [19,20]. Guidelines state
that supervised exercise with adequate warm-up and
cool-down, and gradual progression of intensity or diffi-
culty, may be followed by women with BCRL [21]. This
is based on positive results from large randomised con-
trolled trials of resistance training [22,23] and from
smaller trials covering a variety of other exercise modal-
ities [24] including combined aerobic and resistance ex-
ercise [25], tai-chi [26], gentle exercise with relaxation
[27] and aquatic exercise [28]. Importantly, these trials
have reported no exacerbation of lymphoedema and an
improvement in physical fitness, upper body function
and quality of life.
Currently, there is no published research into the
effects of yoga on BCRL, despite many women with
BCRL stating that they are already using yoga along with
conventional lymphoedema treatment [29]. However,
yoga therapy as part of a holistic treatment for lower
limb lymphoedema in India, has resulted in decreased
levels of lymphoedema, and fewer infections. It focuses
on lymphatic clearing by using specific postures, deep
diaphragmatic breathing, elevation of legs and relaxation
[30].
Yoga can offer a holistic approach to the management
of BCRL as the practices promote progressive physical
postures (asana) with breath awareness, breathing exer-
cises (pranayama), meditation and relaxation. Research
into the efficacy of yoga for women during and after
breast cancer treatment (without lymphoedema) reportsimproved quality of life [31]and immunity [32,33] as well
as reduction of pain [34] and fatigue [35]. Other
improvements have been reported in flexibility [36], grip
strength, shoulder function [37] and body image [38].
These outcomes may be transferrable to women with
BCRL.
The aim of this study is to evaluate the effects of an
eight-week integrated yoga intervention on women with
BCRL. The primary objectives are to evaluate the effect
of regular yoga participation on lymphoedema (amount
of fluid and tissue density), and its associated symptoms
(sensations, pain, fatigue) and to assess its impact on
quality of life. Secondary objectives are to determine the
effect of yoga on the upper body, in particular shoulder
mobility and strength and mobility of the thoracic spine.
A further objective is to investigate participant percep-
tions about the effectiveness of the yoga intervention. In-
formation about daily and weekly physical activity as
well as demographic information will also be collected.
We hypothesise that an eight-week integrated yoga
intervention will have a beneficial effect on BCRL as
indicated by reduced swelling of the affected arm,
reduced tissue density, fewer symptoms of pain, fatigue
and sensations and their limiting effects, improved qual-
ity of life and upper body functioning.
Methods/design
Study design and setting
This study is designed to be a randomised controlled
trial for women with stage one BCRL, as defined by the
International Society of Lymphology [16]. The study will
compare the results of a group who receive an integrated
yoga intervention, to a control group who will continue
to follow current best-practice in self-management of
lymphoedema from a manual given to all participants
pre-randomisation, but who will receive no yoga inter-
vention. The control group will be wait-listed for the
yoga intervention and so will be invited to participate at
the completion of the study.
Measurements will be conducted at baseline (week 0),
after which participants will be randomised to the yoga
intervention or the control group. Further measure-
ments will be made at week 4 (mid-point), week 8 (on
completion of the yoga) and at week 12 (four weeks after
the intervention).
The trial will be held at two locations, Hobart and
Launceston. Both locations will consist of an interven-
tion and control group. The study will be conducted at
Community Health Centres in both locations.
Ethical considerations
The study has been approved by the University of Tas-
mania Social Sciences Ethics committee. Yearly progress
reports will be made to the ethics committee and they
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has been registered with the Australian New Zealand
Clinical Trials Registry (ACTRN12611000202965, http://
www.anzctr.org.au/default.aspx).
All women in the trial will receive information in a
manual specifically developed for this trial on best
current practice for management of secondary lymphoe-
dema, based on the guidelines of the Australasian Lym-
phology Association and Lymphoedema Framework
[16,39].
Women will be advised to continue with their usual
treatment plan during the trial and to seek medical help
in the case of infection or a flare-up of lymphoedema.
Should this occur, women will be advised they can con-
tinue with the trial but told their measurements will not
be included in the results, as it will change their status
with regard to the eligibility criteria.Withdrawal from study
Participants will be able to withdraw from the trial at
any time without prejudice, as set out in the information
sheet distributed at the time of consent.Identification of eligible participants
Recruitment will occur over a two-month period
throughout Tasmania. Key people, including profes-
sionals in the field of lymphoedema and relevant organi-
sations such as the Cancer Council and Breast Screen,
and support and exercise groups such as Encore and
Dragons Abreast, will be contacted and asked to dissem-
inate information about the trial to potential partici-
pants, through flyers and posters.
Media exposure will be sought, including articles in
local newspapers and interviews on local radio. Posters
will be put in major and rural hospitals, Women’s Health
Centres (Hobart, Launceston) and Community Centres.
Individuals interested in participating will be asked to
contact the principal investigator (AL) who will outline
the study, including the yoga intervention, the home-
practice, the methods and dates of measurement, after
ascertaining if they are suitable for participation as per
the inclusion and exclusion criteria. Eligible participants
will be sent an information sheet and informed consent
form. After receiving the forms, they will be telephoned
in order to discuss any questions or concerns about the
trial before returning the signed consent form.
After the signed consent form is returned, participants
will be sent the dates for the trial (measurements and
intervention) as well as a questionnaire with demo-
graphic and medical information to be completed and
brought to baseline measurement. At this time, the man-
ual for current best-practice will also be sent, and fol-
lowed by another phone call to check for clarity.Sample size calculation
An a priori sample size calculation based on clinically
significant changes between groups of between 10-20%
in primary outcome measures with standard deviations
of between 12 and 15% of the mean, or within groups
10% difference with an SD of 20%, indicated that num-
bers of between 13 and 19 participants would be
required per group. Consequently, we plan on recruiting
20 participants per group to allow for a small number of
withdrawals.
Participants
Eligibility criteria based on previous exercise trials for
women with BCRL will be followed [26,40]. Criteria for
inclusion are completion of treatment for breast cancer
in terms of surgery, radiotherapy and chemotherapy at
least 6 months previously; unilateral secondary lymphoe-
dema stage one related to surgery for breast cancer, as
confirmed by a registered lymphoedema therapist; good
English comprehension in order to understand the writ-
ten forms and oral instructions and be able to give
informed consent; aged> 18 years.
Criteria for exclusion are conditions of primary lym-
phoedema, recurrent cancer and other symptoms in-
cluding infection or cellulitis, which would affect the
woman’s lymphoedema and her quality of life adversely;
severe psychological illness, as the yoga intervention
would need to be specific to the person’s psychological
illness in order to improve it; pregnant women and
women with pacemakers, as these conditions are contra-
indicated for the use of bio-impedance spectroscopy –
one of the measuring tools for this study [41]; current
lymphoedema treatment other than self-management, as
this would affect the results.
Women will also be asked to refrain from commen-
cing any new physical activity during the term of the
trial as this could affect results.
Randomisation
An individual not associated with the trial will perform
the randomisation based on a computer- generated ran-
dom number system. Group notification will be in a
sealed envelope given to women after completion of the
baseline measurement.
The yoga intervention
The yoga intervention will consist of a weekly 90-minute
yoga class for eight weeks by a qualified, accredited and
experienced yoga teacher. Participants will also be given
a 45-minute DVD made especially for this trial, with a
shorter version of the class, and instructed to perform it
daily. They will be given a log, in order to record their
home sessions and make relevant comments.
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based on the Satyananda yogaW style of teaching. The
breathing and pranayama, physical postures, meditation
and relaxation techniques have systemised practices that
will be taught to ensure uniformity of practice for out-
comes [42]. This style, with its gentle repetitions of
physical movements followed by rests, and use of modi-
fications, may be well-suited to yoga for BCRL. Options
for modifications will allow an individualised approach
based on comfort, needs and preferences, in both the
class and the home-practice DVD. Practices will be pro-
gressive during the eight weeks of the intervention.
The yoga intervention proposed in this study will con-
sist of slow and deep breathing, a series of moving yoga
postures followed by rests, pranayama, meditation based
on mindfulness practices, and deep relaxation with arm
elevation. The practices will be chosen to promote
lymphatic clearing, improved postural awareness of the
thoracic and shoulder area, as well as stress reduction.
Each yoga session will have appropriate warm-up and
cool-down, following the guidelines of exercise for
women with BCRL. The temperature of the room will be
controlled to between 19–22 degrees Celsius (suitable
for Tasmania) to ensure it does not become too hot,
which can overload the lymphatic system [16].
Primary and secondary outcomes
Characteristics of the sample
Women will complete questionnaires on demographic
information, current health, as well as medical history
pertaining to breast cancer and its treatment, and lym-
phoedema, onset and treatment prior to measurement.
The completed questionnaires will be brought in at base-




All measurements of lymphoedema will be conducted
with the participant resting in a supine position, with any
compression sleeve removed. Due to the effect on the
calculation of lymphoedema, the dominant and affected
arm will be noted, and weight and height measured on
the same equipment each time to calculate BMI.
Extra-cellular fluid
Extra-cellular fluid will be measured according to a
recognized protocol [41], using bio-impedance L-dex™
XCA (Bio-Impedimed, Queensland), with electrodes
placed at anatomical landmarks at the wrist of each arm
and right ankle. An increase in extra-cellular fluid is paral-
leled by a decrease in impedance from the low-frequency
electrical current. The result is recorded as a ratio to the
non-affected limb, taking into account arm dominance[43]. As lymphoedema increases, so does the ratio of im-
pedance [44]. The result, calculated from software pro-
vided by Bio-Impedimed, is recorded as an l-dex reading
and any reading equal or higher than ten is considered
an indication of clinically manifest lymphoedema.
Volume and percentage volume of arm and hand
lymphoedema
Circumferential readings will be based on the protocol
of the Australasian Lymphology Association [45], modi-
fied so the woman is lying not sitting. Both arms will be
marked at the metacarpophalangeal joint, ulnar styloid
and 10, 20, 30, 40 centimetres (cm) from the styloid
process, using a pen and set square on the medial and
lateral aspect of the arm, then circumference measured
at each point by a Job non-stretch tape, recorded in cm.
Finger circumferences will be measured distal to the
web space, and recorded in millimetres (mm). Volume
of lymphoedema and percentage of lymphoedema in the
arm and hand will be calculated using the truncated
cone formula [46] from the addition of circumference
readings, using software provided by Flinders Lymphoe-
dema Clinic, South Australia (SA), which compares the
affected to the non-affected arm. An increase in fluid
volume and % fluid volume readings equates to an in-
crease in level of lymphoedema. Fluid volume will be
recorded as millilitres (ml) and % fluid volume of ml.
Density of fibrous tissue
Density of fibrous tissue will be measured by a digital
tonometer, model 1383 (Bio-medical Engineering, Flin-
ders Medical Centre, SA), validated especially for this
population [47,48], with an established protocol [49].
Tonometer measurements will be taken on the forearm
10 cm from the cubital fossa and on the upper arm
10 cm up from the cubital fossa in the middle of the
lymph territory. Additional measurements will be taken
at the anterior trunk at mid-clavicular line between the
second and third ribs and the posterior trunk between
the acromion and the first thoracic rib in the subscapu-
lar fossa. The digital tonometer measures the resistance
of the tissues to compression - that is, the amount of fi-
brotic induration (collagen build-up) in the superficial
tissues at a given point [46,50]. Each measurement will
be followed by a three-second pause before retesting. A
higher score for the digital tonometer denotes a higher
level of tissue density. The result will be recorded in mm
and the average of three recorded.
Physical sensations associated with lymphoedema
Visual Analogue Scales (VAS) have been validated as an
effective method of recording individual perceptions of
subjective parameters such as pain [51], and adapted in
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lymphoedema [40,52].
A VAS scale that has been developed for this trial will
be used to measure the severity of lymphoedema sensa-
tions which each woman will define, such as heaviness,
tingling, aching. The VAS scale will also measure pain
and fatigue, and the degree to which sensations, pain
and fatigue have limited her activity for that day. The
VAS scale will record what each woman felt on the day
of measurement. The scale is scored as 0 cm being ‘no
discomfort’ and 10 cm being ‘the worst imaginable’.
Quality of life
A validated questionnaire [15], developed specifically to
measure quality of life for people with lymphoedema
(LYMQOL), will be used. Its upper limb version will be
used in this trial. Scores are recorded for the day of
measurement. Total quality of life score is recorded be-
tween 0–10, ten being the best and zero the worst. Its re-
sult is recorded as the number the woman recorded from
1 to 10. Independent scales for function, symptoms, ap-
pearance, emotions, are also included in the question-
naire. Each of these includes several questions which are
marked from 1 to 4, four being the worst. The sum of
answers for each area of function, symptoms, appearance
and emotions are added, then divided by the number of
questions in that section to give a score for each param-
eter. A higher score denotes a lower quality of life asso-
ciated with that parameter. In this way, different aspects
of quality of life can be recorded numerically and com-
pared between intervention and control groups.
Secondary outcomes measures
Range of motion of shoulder
The range of motion (ROM) of the shoulder of the non-
affected, followed by the affected, arm will be measured
using a two-armed goniometer, which has been validated
for clinical trials [53] and used in trials for women with
BCRL [54,55]. An established protocol [56] will be fol-
lowed . Women will sit in a low-back chair with stable
shoulder blades, and suitable back support, their knees
bent to 90° and with their feet at hip width and flat on
the floor. Flexion, abduction and extension of the shoul-
der in the sagittal or coronal planes will be measured
from the starting point of arms in anatomical position.
Internal and external rotation of the shoulder will be
measured from the starting position of the arm abducted
to 90°, forearm pronated and parallel to floor, palm
down, with elbow bent to 90°. To prevent fatigue, the
testing will be conducted in the following order: flexion,
internal rotation, extension, abduction, external rotation.
Endpoint of measurement will be full range, compensa-
tory movements of the shoulder or trunk occurring, or
women experiencing pain or tightness. The final resultwill be recorded in degrees as the best of three attempts.
The higher the score the greater the range of motion.
Strength of shoulder
Muscle strength will be assessed using a Commander
Powertrack II Muscle Tester (JTechMedical, Salt Lake
City, Utah, USA), validated in a healthy population [57]
and used in lymphoedema trials [7,58] following an
established protocol for muscle testing [59]. The partici-
pant will sit in a stable position and the non-affected,
then the affected, arm measured in turn, three times for
each test. The arm will be raised to 90° for measurement
of strength for flexion, horizontal adduction and abduc-
tion. The arm will be positioned slightly across the body
for measurement of strength for pectoralis major and the
arm elevated to 120° for strength of serratus anterior. To
measure the strength of extension, the participant’s arm
will be by her side. Pectoralis minor strength will be
assessed with the participant in supine position. This is
also the order of testing to prevent fatigue.
The strength of the arm or shoulder will be measured
from the force applied against the resisted hand-held
dynamometer, held by the assessor for a count of three
seconds. Measurement will cease when full strength is
applied, compensatory movements of the shoulder or
trunk occur or pain is experienced. The best of three
attempts will be recorded in Newtons (n). A high score
denotes a stronger muscle action.
Grip strength
Hand grip strength will be assessed by using a hand-held
grip dynamometer (Smedleys, TTM, www.stoeltingco.
com), which has been validated for use in a clinical set-
ting [60], and using a protocol common to lymphoedema
trials [58]. The participant will sit in a stable position
with her elbow bent at 90° and close to their body, palm
facing inwards. Grip strength will be assessed by applying
pressure to the dynamometer with the non-affected, fol-
lowed by the affected, hand. Measurement ceases at full
strength or if pain or instability occurs. The best of three
attempts will be recorded in kilograms (kg). A high score
denotes stronger grip strength.
Thoracic spine mobility
Thoracic spine mobility will be measured dynamically
using video analysis in order to quantify the functional
mobility of the spine during flexion/extension, lateral
flexion and rotation following a validated protocol.
[61]. Range of motion will be recorded by a video
camera with backlighting, utilising reflective surface
markers. Reflective markers will be placed on women’s
skin at the following locations: left and right superior
posterior iliac spines (LPSI, RPSI), spinal processes (S1,
L3, L1, T6, T1) and left and right acromion (LACR,
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wall behind, or on the floor around the chair in the
case of rotation, to provide calibration references. At
the initial assessment, the placement of markers will
be measured and recorded on the participant’s data
sheet, to ensure consistency in the placement of mar-
kers at each measurement.
Women will be tested standing in stable anatomical pos-
ition for flexion/extension and lateral flexion with the cam-
era at a distance of two metres, and in stable sitting
position for rotation with the camera one metre overhead.
The test will be performed three times with each move-
ment stopping at the point of full range, instability or pain.
Video footage will be downloaded at the end of each
measurement. Video data will then be analysed using
Quintic™ sports biomechanics video analysis software
9.03 version 14 (www.quintic.com). Measures will be cal-
culated from resting position to range in each directionScreening
Women with confirmed unilateral secondary arm lym
>18 years
6 months post tr
Exclusion c
• Primary lymphoedema, infe
• Psychological illness 











4 week follow up me
Figure 1 Flow chart of trial.and full range, and will be recorded in degrees from soft-
ware specifically made for this trial (Human Life
Sciences, UTAS), following the calculated measures
described in another trial [61]. A higher score denotes
greater movement. After analysis by Quintic, data will be
entered into a specifically designed trial database.
As the use of video analysis with surface markers ap-
plied to the skin may be invasive for women who have
been treated for breast cancer, women will have a choice
of participation in this test.
Physical activity
Physical activity will be recorded at each session as it
may impact other outcomes such as lymphoedema, sen-
sation, pain, fatigue and arm movement. Physical activity
in the week prior to each measurement period will be
reported using the International Physical Activity Ques-
tionnaire (IPAQ-2005) short form, proven reliable in the 
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questionnaire measures the amount of vigorous, moder-
ate and walking activity in intensity and duration, as well
as the number of minutes in sitting. The total time in
each activity is multiplied by an intensity value to calcu-
late total weekly activity reported in MET.min-1. The
total MET.min-1 score will also be given a value of
1 = light; 2 =moderate; 3 = high. Sitting time is recorded
as a total number of minutes for that week.
Physical activity for that day will be recorded on the
VAS scale as a number from 0-10 with 0 indicating no
activity and 10 indicating constant activity.
Interview for yoga intervention women
A 20-minute audio-taped interview will be held at week 8
for the yoga intervention group and will be carried out by
an independent assessor. Questions will be open-ended,
in relation to the yoga sessions and DVD. Recorded inter-
views will be transcribed in full. An iterative-thematic ap-
proach will be used to analyse data by two researchers
independently, then results compared and further analysis
completed, by reporting data in themes and sub-themes
according to frequency.
Study measures at baseline and weeks 4, 8 and 12
All staff involved in measurements will be trained prior
to commencement of baseline testing and useTable 1 Outcome measurements at baseline, weeks 4, 8, 12
Baseline week 0 Week 4
measurements Measurements-after
4 weeks interventio
Collection of medical, demographic questionnaires
Log of daily yoga practice to yoga group Collection of daily yo
Lymph measures: Lymph measures:
• Bio-impedance • Bio-impedance
• Circumference • Circumference
• Tonometer • Tonometer
• VAS symptoms • VAS symptoms
Weight/height BMI Weight/BMI
Arm measures: Arm measures:
• Arm strength • Arm strength
• Shoulder ROM • Shoulder ROM
QOL: QOL:
LYMQOL questionnaire LYMQOL questionnai
Physical activity: Physical activity:
• IPAQ –short form • IPAQ –short form
• VAS day’s activity • VAS day’s activity
Thoracic spine – sub group:
• Spinal ROM videostandardised protocol and validated instruments. Two
qualified lymphoedema therapists will take the lymphoe-
dema measurements, one in Hobart, one in Launceston.
Other staff will be the same at both locations. All asses-
sors will be blinded to group allocation and to previous
results. Each measurement will be performed by the
same assessor at each time-point.
Participants will be advised to abstain from alcohol
12 hours prior to testing, caffeine and heavy exercise
two hours before and be allocated a time that will not
change during the trial to ensure consistency of readings
for lymphoedema levels.
Measurements for the thoracic spine sub-group will be
held the day after the other measurements at baseline,
weeks 8 and 12.
All equipment will be calibrated prior to each meas-
urement period.
All data will be recorded onto a case record form for
each woman then transcribed into a specifically designed
trial database.
The study flow is summarized in Figure 1 and the
study measurements in Table 1.Measurements at weeks 4, 8, 12
Measurements and sequence of measurements will be







ga log Collection of daily yoga log
Lymph measures: Lymph measures:
• Bio-impedance • Bio-impedance
• Circumference • Circumference
• Tonometer • Tonometer
• VAS symptoms • VAS symptoms
Weight/BMI Weight/BMI
Arm measures: Arm measures:
• Arm strength • Arm strength
• Shoulder ROM • Shoulder ROM
QOL: QOL:
re LYMQOL questionnaire LYMQOL questionnaire
Physical activity: Physical activity:
• IPAQ –short form • IPAQ –short form
• VAS day’s activity • VAS day’s activity
Thoracic spine – sub group: Thoracic spine – sub group:
• Spinal ROM video • Spinal ROM video
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DVD
A protocol will be put in place should a woman in the
intervention have to miss a class, so that another class
may be organised when possible. Attendance at the yoga
class will be recorded weekly and DVD compliance self-
recorded in a log, collected at weeks 4 and 8.Data analysis
Medical and demographic information will be analysed
using descriptive analysis within SPSS (version 19SPSS
Inc. IBM, USA 2010) to calculate means and standard
deviations or percentage values. Differences between
groups will be assessed using t-tests for comparing con-
tinuous variables and chi-square tests for categorical
variables.
All statistical analyses for quantitative measurements will
be performed using STATA statistical software (version 12;
1985-2011; STATA corp.; College Station; Texas, USA).
Binary categorical data will be analysed for variability be-
tween the groups using logistic regression. Parametric lon-
gitudinal data will be analysed via mixed methods linear
regression. Non-parametric data will use ordinal logistic re-
gression. Post-hoc testing will be performed on both para-
metric and non-parametric data using the Holms test to
locate the means that are significantly different. Statistical
significance will be set at p< 0.05.
Qualitative data from interviews will be analysed using
an iterative-thematic approach.Discussion and conclusion
The aim of this trial is to determine the effect of a yoga
intervention on women with secondary arm lymphoe-
dema as a result of breast cancer treatment by compar-
ing the measurements of the intervention group with
those of the control group, as well as to assess the per-
ceived effects of yoga on the women in the intervention
group by interview.
As no such trial has occurred up to this time, the
results will assist in determining the effects of yoga on
aspects relating to the lymphoedema, quality of life and
upper body functioning for women with BCRL in the
hope of finding another safe self-care option for women
with BCRL. Finally, the methodology will inform future
studies with larger numbers, as well as teaching guide-
lines for use by qualified yoga teachers.Competing interests
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